Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Financial documents
General Shareholders’ meetings
Letters to shareholders – Regulated information
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
Retour aux communiqués
Date
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Téléchargez